Try our Advanced Search for more refined results
Life Sciences
- 
									October 21, 2025
									Investors Tell Chancery CytoDyn Board Ignored Drug SchemeStockholders of CytoDyn Inc. have filed a consolidated derivative complaint in the Delaware Chancery Court, accusing the company's leadership of wrongfully refusing to investigate and sue its former CEO and others over an aligned scheme to mislead investors about the company's flagship drug. 
- 
									October 21, 2025
									J&J Unit Seeks Sanctions Over Doc's Deleted Talc EmailsA Johnson & Johnson subsidiary is asking a Virginia federal court to sanction a doctor who it alleges wrote a false article linking its talc products to mesothelioma, saying the only explanation for his policy of deleting all emails as soon as he sends or reads them is to destroy evidence. 
- 
									October 21, 2025
									Full Fed. Circ. Won't Rehear $125M Medtronic Patent VerdictThe full Federal Circuit has declined to revisit a panel decision that overturned a $125 million patent infringement judgment against Medtronic's CoreValve unit, letting stand a precedential opinion addressing the doctrine of prosecution history estoppel. 
- 
									October 21, 2025
									J&J Appeals $25M Loss In Conn. Builder's Asbestos CaseJohnson & Johnson has appealed its losses in a Connecticut real estate developer's asbestos lawsuit, telling state trial and appellate courts that it plans to challenge denials of multiple bids to reverse a $15 million jury verdict plus an additional $10 million in punitive damages awarded by a judge. 
- 
									October 21, 2025
									PE Giants Ink $18.3B Deal For Hologic Amid Megadeal BlitzHologic Inc. said Tuesday it will be acquired by a private equity consortium in a deal valuing the Wachtell-advised medical technology company around $18.3 billion, marking one of the largest leveraged healthcare buyouts in recent years. 
- 
									October 21, 2025
									Novartis Says Alexion's 'Block The Cause' Ads Are FalseNovartis Pharmaceuticals Corp. is suing rival Alexion Pharmaceuticals Inc. in Delaware federal court, alleging that Alexion's "Block the Cause" ad campaign for its Ultomiris product falsely implies that Novartis' own treatment is less effective or even dangerous. 
- 
									October 20, 2025
									Novo Nordisk Trial Kicks Off Over Kickback AllegationsLawyers in a federal whistleblower lawsuit against drugmaker Novo Nordisk Inc. on Monday offered to take jurors "behind the curtain" of what they claimed was an illegal scheme by the pharmaceutical company to bribe doctors and patients in order to boost sales of a pricey hemophilia drug, NovoSeven. 
- 
									October 20, 2025
									Drugmakers Say Conn. Law Illegally Extends Beyond StateA group of generic drug manufacturers has asked a Connecticut federal court to block the enforcement of a new price-control law against sales that occur outside of Connecticut, claiming that the law violates the U.S. Constitution. 
- 
									October 20, 2025
									Biotech Co. Asks SEC For Emergency Delisting PauseChinese biotechnology company Shineco Inc. has asked the U.S. Securities and Exchange Commission for an emergency stay of Nasdaq's suspension and delisting of its securities, arguing it will likely succeed in its pending appeal to the stock exchange. 
- 
									October 20, 2025
									Sterigenics Nears Win In Georgia Ethylene Oxide LitigationSterigenics Inc. notched two significant wins in sprawling litigation over its alleged emissions of carcinogenic ethylene oxide at an Atlanta-area plant, as a Georgia state court judge tossed residents' specific causation claims and allegations that the plant's activities constituted a private nuisance. 
- 
									October 20, 2025
									Tylenol Maker Tells FDA Not To Add Autism WarningTylenol maker Kenvue on Friday told the U.S. Food and Drug Administration to reject a call to add warnings about the risk of using acetaminophen during pregnancy, saying that "expansive" scientific evidence shows there is no proven link between the over-the-counter drug and autism. 
- 
									October 20, 2025
									Ex-GC Says Honeywell Can't Boot Her Age Bias Suit To ChinaA former vice president and general counsel for a Honeywell subsidiary said the conglomerate can't skirt her age discrimination claims by punting the case to China — where she lived and worked during her employment — because she has no legal remedy under Chinese law. 
- 
									October 20, 2025
									More Fed. Workers Added To TRO Blocking Shutdown LayoffsA California federal judge who blocked the Trump administration from laying off workers from two unions representing thousands of federal workers has expanded her temporary restraining order to include three more unions and also clarified that the order covered workers with union contracts that the administration is seeking to ditch. 
- 
									October 20, 2025
									Catching Up With Delaware's Chancery CourtThis past week, the Delaware Chancery Court and Supreme Court handled a crowded corporate docket, weighing blockbuster merger appeals, shareholder settlement objections, fights over control involving an NBA franchise and a high-profile appeal from Elon Musk involving a massive payday from Tesla. 
- 
									October 20, 2025
									Top Court Won't Hear Chicago Hospital's Medicaid DisputeThe U.S. Supreme Court on Monday refused to review a decision by the full Seventh Circuit holding that a Chicago hospital can't sue the state of Illinois to force the managed care organizations it contracts with to make timely Medicaid payments, rejecting a petition that argued another case on the high court's docket "will likely decide the outcome" in this one. 
- 
									October 20, 2025
									High Court Won't Hear Hospital Vax Mandate CaseThe U.S. Supreme Court said Monday it won't review a decision backing a hospital's termination of a group of workers who refused to get COVID-19 vaccinations. 
- 
									October 20, 2025
									Justices Won't Review Merck's Immunity From Vaccine ClaimsThe U.S. Supreme Court refused Monday to review a decision immunizing Merck & Co. from claims that it blocked competition by making false submissions to federal regulators for its mumps vaccine. 
- 
									October 17, 2025
									Jury Clears Disney Unit Of Bias In '9-1-1' Actor's Vax FiringA California federal jury cleared a Disney-owned television unit of religious discrimination Friday for firing an actor from the ABC show "9-1-1" after he refused to receive a COVID-19 vaccination in 2021, finding he did not sincerely hold a religious belief opposing vaccinations. 
- 
									October 17, 2025
									Settlement Balk Jeopardizes $32M Class Deal In ChanceryAn attorney for a large Emisphere Technologies stockholder told a Delaware vice chancellor on Friday that Court of Chancery refusal to allow an opt-out from a $32 million class settlement in a suit challenging the biotech company's $1.8 billion sale price "would have to be addressed by the U.S. Supreme Court." 
- 
									October 17, 2025
									Mixed Discretionary Denial Batch Caps Off Big Week For PTABDeputy U.S. Patent and Trademark Office Director Coke Morgan Stewart allowed 19 Patent Trial and Appeal Board petitions to go forward while denying 21 others on Friday, concluding a week that saw major reforms at the PTAB. 
- 
									October 17, 2025
									Insys Ex-CEO Babich Agrees To $30M Trustee Deal In Del.Former Insys Therapeutics CEO Michael Babich has consented to a $30 million settlement amid a bankruptcy trustee's efforts to recover tens of millions in damages from company officials tied to Insys' aggressive marketing of the opioid painkiller Subsys, according to a Delaware Court of Chancery settlement filed early on Friday. 
- 
									October 17, 2025
									NJ Parents Keep Fighting State Over Storage Of Babies' DNAAcross the U.S., health departments draw small blood samples from newborns' heels to test for metabolic and genetic disorders. After a new mother discovered that New Jersey police had used DNA extracted from such samples in criminal investigations, she signed on as plaintiff in a suit that says parents have a right to refuse these blood draws. 
- 
									October 17, 2025
									3rd Circ. Says No Duty To Inform Criminal Clients Of LiabilityThe Third Circuit in a precedential ruling Friday declined to apply immigration precedent concerning counsel's obligation to advise their criminal defendant clients about deportation risks associated with prosecutions to the civil setting, holding that the standard applies only in highly specific circumstances. 
- 
									October 17, 2025
									Federal Courts To Scale Back Operations Amid ShutdownThe federal court system has run out of money and will scale back operations beginning Monday as a result of the ongoing government shutdown, possibly leading to case delays. 
- 
									October 17, 2025
									Boston Scientific Buying Rest Of Pain Therapy Biz For $533MBoston Scientific Corp. said on Friday it will buy the remaining stake in Nalu Medical Inc. it does not already own for about $533 million, strengthening its position in neuromodulation therapies for chronic pain. 
Expert Analysis
- 
								
								What Prop 65 Ruling Means For Cosmetics, Personal Care Biz  A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis. 
- 
								Series Adapting To Private Practice: From Va. AUSA To Mid-Law  Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers. 
- 
								
								2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls  Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis. 
- 
								
								Rebutting Price Impact In Securities Class Actions  Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten. 
- 
								
								7 Document Review Concepts New Attorneys Need To Know  For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke. 
- 
								
								Ruling On Labor Peace Law Marks Shift For Cannabis Cos.  Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin. 
- 
								
								Fed. Circ. Rulings Refine Patent Claim Construction Standards  Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft. 
- 
								
								How Value-Based Patent Fees May Shape IP Strategies  If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary. 
- 
								
								Agentic AI Puts A New Twist On Attorney Ethics Obligations  As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG. 
- 
								
								Using Reissue Applications To Strategically Improve Patents  Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield. 
- 
								
								FDA Transparency Plans Raise Investor Disclosure Red Flags  The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter. 
- 
								Series Being A Professional Wrestler Makes Me A Better Lawyer  Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability. 
- 
								
								Patent Claim Lessons From Fed. Circ.'s Teva Decision  The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley. 
- 
								Series Law School's Missed Lessons: Adapting To The Age Of AI  Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor. 
- 
								
								Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning.jpg)  A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.